# A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

> **NCT05089630** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 339 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **BIOLOGICAL:** Pentamer (low)/gB(low)/Adjuvant vaccine
- **BIOLOGICAL:** Pentamer (med)/gB(low)/Adjuvant vaccine
- **BIOLOGICAL:** Pentamer (med)/gB(med)/Adjuvant vaccine
- **BIOLOGICAL:** Pentamer (high)/gB(med)/Adjuvant vaccine
- **COMBINATION_PRODUCT:** Placebo (saline)

## Key facts

- **NCT ID:** NCT05089630
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-14
- **Primary completion:** 2025-04-02
- **Final completion:** 2025-04-02
- **Target enrollment:** 339 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05089630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05089630, "A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05089630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*